Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00304512
Other study ID # FAB-CL-204
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 7, 2006
Est. completion date May 9, 2008

Study information

Verified date October 2018
Source Amicus Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.


Description:

This was a Phase 2, open-label study in female participants with Fabry disease. The study consisted of a 4-week screening period, during which participants' galactosidase (GLA) genotype was assessed for α-galactosidase A (α-Gal A) activity in response to migalastat. Participants were required to have α-Gal A activity responsive to migalastat. The study consisted of a 12-week treatment period, followed by an optional 36-week extension period. Participants received migalastat once every other day (QOD) for 12 weeks during the treatment period and the optional 36-week extension period for a total treatment duration of up to 48 weeks. Participants were stratified by α-Gal A enzyme activity (high >40%, and low ≤40%) then randomly assigned to receive migalastat at 1 of 3 specified dose levels (50, 150, or 250 milligrams [mg]).


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date May 9, 2008
Est. primary completion date May 9, 2008
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Females between 18 and 65 years of age (inclusive)

- Heterozygous for Fabry disease

- Had a confirmed diagnosis of Fabry disease with a documented missense gene mutation (individual or familial)

- Had enhanceable enzyme activity based on in vitro tests

- Were naïve to enzyme replacement therapy (ERT) and other therapies, except for palliative therapies for the signs and symptoms of Fabry disease, or stopped ERT for at least 18 weeks

- Had end organ dysfunction, even minimal, demonstrated by abnormal electrocardiogram (ECG) or evidence of left ventricular hypertrophy documented by echocardiogram or by cardiac biopsy; or renal insufficiency documented by common clinical assessments such as creatinine and glomerular filtration rate or by renal biopsy; or brain tissue dysfunction as documented by evidence of stroke (clinically or imaging); or peripheral nervous tissue dysfunction documented by complaints of intolerance to heat or cold, decreased vibratory sense and proprioception, decreased ability to perspire, or acroparesthesia.

- Were willing to undergo 2 renal and 3 skin biopsies

- Agreed to be sexually abstinent or practice an effective method of contraception when engaging in sexual activity during the course of the study and for a period of 30 days following their completion of the study for women of childbearing potential.

- Were willing and able to provide written informed consent

Exclusion Criteria:

- Pregnant or lactating

- History of organ transplant

- History of significant disease other than Fabry disease (for example, end-stage renal disease; Class III or IV heart disease [per the New York Heart Association classification]; current diagnosis of cancer, except for basal cell carcinoma of the skin; diabetes [unless hemoglobin A1c =8]; or neurological disease that would have impaired the participant's ability to participate in the study)

- Serum creatinine >176 micromoles/liter on Day -2

- Screening 12-lead ECG demonstrating corrected QT interval >450 milliseconds

- Pacemaker or other contraindication for magnetic resonance imaging scanning

- Taking a medication prohibited by the protocol: Fabrazyme® (agalsidase beta), Replagal™ (agalsidase alfa), Glyset® (miglitol), Zavesca® (miglustat), or any experimental therapy for any indication

- Participated in a previous clinical trial in the last 30 days

- Any other condition which, in the opinion of the investigator would jeopardize the safety of the participant or impact the validity of the study results.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
migalastat HCl


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Amicus Therapeutics

Countries where clinical trial is conducted

United States,  Australia,  Brazil,  Canada,  France,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) TEAEs were defined as any adverse event with start date on or after administration of study drug or pre-existing conditions that worsened on or after the start of the first study drug administration (on Day 1). A severe adverse event was defined as an adverse event that was incapacitating and required medical intervention. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through Week 48 is presented. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. Day 1 (after dosing) through Week 48
Secondary PK: Area Under The Concentration Versus Time Curve (AUC) After Administration Of Migalastat The AUC to the last measurable concentration (AUC0-t) was evaluated in plasma following a single oral dose of migalastat on Day 1 and following multiple oral doses on Day 14 (2 weeks) and Day 84 (12 weeks). All samples were collected on each dosing day. 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, and 10 hours (postdose)
Secondary a-Gal A Activity In Leukocytes At Baseline, Week 12, And Week 48 Leukocytes were isolated from whole blood and lysed, and a-Gal A activity was measured using a validated fluorometric assay, with catalysis to fluorescent 4-methylumbelliferone (4-MU) as the activity measure. The activity values obtained were normalized to protein (measured using a colorimetric assay) and reported as enzyme activity (nanomole [nmol] 4-MU/hr) per mg of protein. On Day 1 of the first visit and at every visit thereafter, the samples were collected prior to dosing with migalastat. a-Gal A activity in leukocytes are presented by individual participants. Baseline, Week 12 (end of treatment period), Week 48 (end of extension period)
See also
  Status Clinical Trial Phase
Recruiting NCT04893889 - Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease. N/A
Completed NCT04455230 - A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190 Phase 1/Phase 2
Completed NCT01218659 - Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease Phase 3
Withdrawn NCT04189601 - Complement Activation in the Lysosomal Storage Disorders
Completed NCT03500094 - Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) Phase 3
Withdrawn NCT04143958 - To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease Phase 4
Recruiting NCT02994303 - Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy N/A
Completed NCT01947634 - Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study. N/A
Recruiting NCT01695161 - Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer. N/A
Completed NCT01853852 - A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects Phase 1
Completed NCT00701415 - A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms Phase 3
Completed NCT00068107 - Dosing Study of Replagal in Patients With Fabry Disease Phase 2
Completed NCT01997489 - Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. Phase 4
Recruiting NCT06007768 - Autoimmune and Inflammatory Response Biomarkers in Fabry Disease
Recruiting NCT05698901 - Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
Active, not recruiting NCT03305250 - Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease N/A
Terminated NCT00526071 - Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study Phase 2
Active, not recruiting NCT03566017 - Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease Phase 3
Recruiting NCT06065605 - Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease
Recruiting NCT06052800 - Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan